EU OKs Roche`s Avastin for ovarian cancer
Zurich: The European Commission has approved Roche`s drug Avastin for treating women with newly diagnosed, advanced ovarian cancer, offering new options to sufferers previously limited to surgery and chemotherapy.
The Swiss drugmaker is the world`s largest maker of cancer drugs. The EU`s approval was granted for Avastin in combination with standard chemotherapy, it said in a statement on Friday.
"Today`s approval of Avastin marks the first major treatment advance in newly diagnosed ovarian cancer in 15 years," said Chief Medical Officer Hal Barron. "This is the fifth tumor type for which Avastin has been approved in Europe, making it one of few biologic drugs indicated for multiple cancers."
In two late-stage studies, Roche found that women with newly diagnosed advanced ovarian cancer who used Avastin and chemotherapy and then continued on just Avastin lived quite a bit longer without their disease getting worse compared with those who received only chemotherapy.
Ovarian cancer is the most deadly of the gynecological cancers, with 140,000 women dying from the disease each year globally, Roche said.
More from India
More from World
More from Sports
More from Entertaiment
- Japan PM pledges to invest $ 30 billion in Africa by 2018
- Kedar Jadhav, Shreyas Iyer power India A to easy six-wicket win
- Talks on Kashmir issue needed, want peace restored in Valley: Pak High Commissioner Abdul Basit
- Gold rebounds on jewellers' buying, silver jumps Rs 280/kg
- US Open 2016: Saketh Myneni advances to main draw